AIBullisharXiv – CS AI · 3d ago7/10
🧠Researchers introduce MolLingo, a multi-agent AI system that automates molecular design by coordinating specialized agents through shared memory and domain-specific tools. The system uses BRICS-based Fragment Enumeration to represent molecules in chemically meaningful ways that LLMs can reason about effectively, achieving superior performance on drug design benchmarks compared to frontier models like GPT-5.
🧠 GPT-5
AIBullishMIT Technology Review · May 227/10
🧠During Google I/O, DeepMind CEO Demis Hassabis stated we are approaching the "singularity," signaling that AI-driven scientific advancement is accelerating rapidly. The keynote highlighted Google's positioning of AI as a transformative force for research and development across industries.
🏢 Google
AIBullisharXiv – CS AI · May 127/10
🧠Researchers introduce MolWorld, a novel AI framework that optimizes molecular structures for drug discovery by modeling actionable pathways between molecules. Unlike existing methods, MolWorld ensures discovered candidates are chemically reachable from known compounds through valid intermediate steps, making them practically viable for lead optimization.
AIBullisharXiv – CS AI · May 127/10
🧠Researchers introduce Yeti, a compact protein structure tokenizer that converts protein structures into discrete tokens for multimodal AI models. The approach achieves superior codebook utilization and token diversity while maintaining competitive reconstruction accuracy with 10x fewer parameters than existing solutions, enabling efficient joint generation of protein sequences and structures.
AIBullisharXiv – CS AI · May 117/10
🧠Researchers have developed an automated framework to generate a large-scale dataset of 163,000 molecule-description pairs by combining rule-based chemical nomenclature parsing with LLM guidance, achieving 98.6% precision in aligning molecular structures with natural language descriptions. This addresses a critical bottleneck in training language models for chemistry applications where manual annotation is prohibitively expensive.
🏢 Hugging Face
AIBullisharXiv – CS AI · May 117/10
🧠FlashMol represents a major breakthrough in computational drug discovery by generating high-quality 3D molecular conformations in just 4 steps, compared to hundreds required by traditional diffusion models. The technique achieves 250x acceleration in sampling speed while matching or exceeding the quality of slower teacher models, potentially transforming the economics of large-scale in silico screening.
AIBullisharXiv – CS AI · May 117/10
🧠Researchers developed an LLM-based agent system for identifying competing drugs in clinical indications, achieving 83% recall compared to 65% and 60% for competitor systems. The agent validates results using an LLM-as-a-judge approach to minimize hallucinations, reducing biotech due diligence analysis time from 2.5 days to 3 hours in production deployment.
🏢 OpenAI🏢 Perplexity
AIBullisharXiv – CS AI · May 117/10
🧠Researchers introduce DualLGD, a novel dual-stream diffusion architecture for generating molecular structures from mass spectra data. The method achieves 3x improvement over previous state-of-the-art by separating atom-level and bond-level reasoning into dedicated computation streams, addressing a fundamental circular dependency problem in molecular generation.
AI × CryptoBullishBlockonomi · May 107/10
🤖Bittensor Subnet 68 has screened over 11 million molecules across nine disease targets using decentralized computing, demonstrating a practical application of blockchain technology in pharmaceutical research. The subnet operates three live competitions rewarding computational contributions through its Yuma Consensus mechanism, enabling companies like Metanova Labs to conduct drug discovery at reduced operational costs.
$TAO
AI × CryptoBullishCrypto Briefing · May 97/10
🤖Bittensor's SN68 subnet is being leveraged by Metanova Labs to accelerate pharmaceutical research and development through decentralized AI infrastructure. While this application demonstrates potential to democratize drug discovery and reduce costs, significant validation challenges remain before decentralized approaches can meaningfully compete with traditional pharma workflows.
$TAO
AIBullisharXiv – CS AI · Apr 207/10
🧠Researchers have developed an exascale workflow using graph foundation models trained on 544+ million atomistic structures to accelerate materials discovery. The system can screen 1.1 billion structures in 50 seconds—a task requiring years of traditional computation—and demonstrates strong transfer learning capabilities across diverse chemical applications.
AIBullishBlockonomi · Apr 177/10
🧠OpenAI has launched GPT-Rosalind, an AI model designed to accelerate pharmaceutical drug discovery, partnering with major life sciences companies including Amgen, Moderna, and Thermo Fisher. The model represents a significant application of advanced AI technology beyond traditional software domains, with potential to compress drug development timelines and reduce research costs.
🏢 OpenAI
AI × CryptoBullishCrypto Briefing · Mar 267/10
🤖Metanova Labs is revolutionizing drug discovery by using Bittensor's decentralized AI network to screen billions of molecules efficiently. The platform utilizes combinatorial reactions to expand screening possibilities to 65 billion compounds and implements dual incentive mechanisms to drive innovation in pharmaceutical research.
$TAO
AIBullisharXiv – CS AI · Mar 117/10
🧠Researchers introduce Logos, a compact AI model that combines multi-step logical reasoning with chemical consistency for molecular design. The model achieves strong performance in structural accuracy and chemical validity while using fewer parameters than larger language models, and provides transparent reasoning that can be inspected by humans.
AIBullisharXiv – CS AI · Mar 56/10
🧠Researchers developed a new AI-powered framework for crystal structure prediction that uses large language models and symmetry-driven generation to overcome computational bottlenecks. The approach achieves state-of-the-art performance in discovering new materials without relying on existing databases, potentially accelerating materials science research.
AIBullisharXiv – CS AI · Mar 57/10
🧠Researchers have introduced Mozi, a dual-layer architecture designed to make AI agents more reliable for drug discovery by implementing governance controls and structured workflows. The system addresses critical issues of unconstrained tool use and poor long-term reliability that have limited LLM deployment in pharmaceutical research.
AIBullisharXiv – CS AI · Mar 57/10
🧠Researchers introduce MMAI Gym for Science, a training framework for molecular foundation models in drug discovery. Their Liquid Foundation Model (LFM) outperforms larger general-purpose models on drug discovery tasks while being more efficient and specialized for molecular applications.
AIBullisharXiv – CS AI · Mar 46/103
🧠Researchers developed a Neuro-Symbolic Agentic Framework combining machine learning with LLM-based reasoning to predict colorectal cancer drug responses. The system achieved significant predictive accuracy (r=0.504) and introduces 'Inverse Reasoning' for simulating genomic edits to predict drug sensitivity changes.
AIBullisharXiv – CS AI · Mar 47/102
🧠Researchers developed RxnNano, a compact 0.5B-parameter AI model for chemical reaction prediction that outperforms much larger 7B+ parameter models by 23.5% through novel training techniques focused on chemical understanding rather than scale. The framework uses hierarchical curriculum learning and chemical consistency objectives to improve drug discovery and synthesis planning applications.
$ATOM
AIBullisharXiv – CS AI · Mar 37/103
🧠Researchers developed mCLM, a 3-billion parameter modular Chemical Language Model that generates functional molecules compatible with automated synthesis by tokenizing at the building block level rather than individual atoms. The AI system outperformed larger models including GPT-5 in creating synthesizable drug candidates and can iteratively improve failed clinical trial compounds.
AIBullisharXiv – CS AI · Mar 37/103
🧠Researchers have developed FROGENT, an AI multi-agent system that uses large language models to automate the entire drug discovery pipeline from target identification to synthesis planning. The system outperformed existing AI approaches across eight benchmarks and demonstrated practical applications in real-world drug design scenarios.
AIBullishGoogle DeepMind Blog · Nov 257/102
🧠AlphaFold has significantly accelerated scientific research and biological discovery over the past five years. The AI system has enabled breakthroughs in protein structure prediction, fueling innovation across the global scientific community.
AIBullishGoogle DeepMind Blog · Oct 237/103
🧠Google has launched a new 27 billion parameter foundation model for single-cell analysis, built on the Gemma family of open models. The model has reportedly helped discover a new potential cancer therapy pathway, demonstrating practical medical applications of AI technology.
AIBullishGoogle DeepMind Blog · Oct 97/105
🧠Demis Hassabis and John Jumper have been awarded the Nobel Prize in Chemistry for developing AlphaFold, an AI system that predicts 3D protein structures from amino acid sequences. This recognition highlights the transformative impact of AI in scientific research and drug discovery.
AIBullisharXiv – CS AI · 3d ago6/10
🧠Researchers introduce ProtLiD², a discrete diffusion model that co-designs protein sequences and structures while conditioning on ligand information, achieving significant improvements in fold confidence and ligand-binding accuracy compared to existing methods. The model demonstrates practical advantages in both whole-protein and active-site pocket design tasks.
🏢 Meta
